Research study Program year 2022 Source: CMS Open Payments

A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis

ClinicalTrials.gov NCT04178967

Research payments

$3,740,645

108 payments

Through program year 2022, $3,740,645 in research payments was reported against A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis, across 108 payments, paid by Eli Lilly and Company.

Paid by: Eli Lilly and Company
ClinicalTrials.gov: NCT04178967

By program year

3 rows

Year	Kind	Amount	Payments
2022	Research	$498,076	35
2021	Research	$2,058,204	38
2020	Research	$1,184,364	35

Breakdown

Who paid Research payments · program years 2020–2022

Eli Lilly and Company $3,740,645 108 payments

Who received the money Research payments · program years 2020–2022

Interspond Llc Organisation paid for research $789,781 9 payments
Elias Research Associates LLC Organisation paid for research $309,160 3 payments
La Universal Research Center Inc Organisation paid for research $251,469 3 payments
Arlington Research Center INC Organisation paid for research $223,521 3 payments
Bukhalo Michael MD Organisation paid for research $188,224 3 payments
Michael Heffernan Dermatology · San Luis Obispo, CA $186,685 3 payments
Wdc Cosmetic And Research Pllc Organisation paid for research $138,411 3 payments
Solutions Through Advanced Research Organisation paid for research $132,391 3 payments
University Clinical Trials INC Organisation paid for research $128,215 2 payments
Advanced Medical Research INC Organisation paid for research $119,463 3 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

10 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.